Search Clinical Trials in the EU

Duration

Visits

Phase

Intake methods

Cost Reimbursement

Drugs

Locations

Clinical Specialty

381-400 of 991 trials

Atopic Dermatitis: Amlitelimab Treatment Study

We are studying two dosing schedules of amlitelimab for people aged 12 and older with moderate-to-severe atopic dermatitis. The goal is to see if it helps maintain treatment response compared to stopping treatment.

Atopic Dermatitis1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteAllergologyDermatology

ROS1-Positive Lung Cancer: REPotrectinib Study

We are testing a new treatment for patients with ROS1-positive non-small cell lung cancer and active brain metastasis. The study aims to see how well it works in shrinking brain tumors and to assess its safety.

ROS1-positive Non-Small Cell Lung Cancer with Brain Metastasis1-2 yearsEfficacy phase (II)Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementNeurologyOncology

Chronic Myeloid Leukemia: Asciminib for Kids

We are studying the safety and appropriate dose of asciminib in children with chronic myeloid leukemia. This research aims to ensure the medication is safe and effective for young patients who have already tried other treatments.

Philadelphia Positive Chronic Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)16-20 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementOncologyPediatrics

Alpha-1 Antitrypsin Deficiency Emphysema: SAR447537 Study

We are studying the long-term safety of SAR447537 in adults with alpha-1 antitrypsin deficiency emphysema. The trial will also evaluate its effects on lung health and how the body processes the treatment.

Alpha-1 Antitrypsin Deficiency (AATD) Emphysema>2 yearsEfficacy phase (II)No Placebo Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicinePulmonology

Meningococcal Vaccine Study for Infants and Toddlers

We are investigating a new meningococcal vaccine to see how well it works and its safety compared to an existing vaccine in healthy infants and toddlers. This study focuses on children receiving their first doses at 6-7 months and a booster at 12-13 months.

Meningococcal Infection6-12 monthsConfirmation phase (III)≤5 visits No Placebo Standard Medicines Cost ReimbursementInfectious DiseasesPediatrics

Kidney Transplant Rejection: Efgartigimod PH20 SC

We are studying a new treatment for kidney transplant recipients facing antibody-mediated rejection. The trial aims to evaluate the safety and how well this medication works compared to a placebo.

Antibody-Mediated Rejection1-2 yearsEfficacy phase (II)16-20 visits Standard Medicines Cost ReimbursementInternal MedicineNephrology

Systemic Lupus Erythematosus: Dapirolizumab Pegol Study

We are studying whether dapirolizumab pegol can improve symptoms in people with moderately to severely active systemic lupus erythematosus. This trial will also assess the safety of this new treatment when added to standard care.

Systemic Lupus Erythematosus6-12 monthsConfirmation phase (III)Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicineRheumatology

Recurrent Low-Grade Serous Ovarian Cancer: Avutometinib and Defactinib Study

We are studying a new combination therapy for patients with recurrent low-grade serous ovarian cancer to see if it helps them live longer and improves their quality of life compared to standard treatments.

Recurrent Low-Grade Serous Ovarian Cancer1-2 yearsConfirmation phase (III)No Placebo Investigational Medicines Cost ReimbursementGynecology and ObstetricsOncology

Tolvaptan for Children with Autosomal Recessive Polycystic Kidney Disease

We are studying the safety and effects of tolvaptan in infants and children with ARPKD. The trial aims to see if it helps reduce the need for kidney treatments.

Autosomal Recessive Polycystic Kidney DiseaseConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteNephrologyPediatrics

Zanidatamab for Advanced HER2-Positive Biliary Tract Cancer

We are studying whether zanidatamab combined with standard chemotherapy helps patients with advanced HER2-positive biliary tract cancer more than standard chemotherapy alone. This trial aims to evaluate its effectiveness and safety.

Biliary Tract CancerConfirmation phase (III)No Placebo Investigational Medicines Cost ReimbursementOncology

Advanced Solid Tumors: GTAEXS617 Treatment Study

We are testing a new treatment called GTAEXS617 for patients with advanced solid tumors to see how safe it is and whether it can help fight the cancer. This study will look at the treatment alone and with standard therapies.

Ovarian Epithelial CancerColorectal AdenocarcinomaNon-Small Cell Lung Cancer6-12 monthsSafety phase (I)Efficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementOncology

HER3-Targeted Imaging with Patritumab Deruxtecan

We are studying the best dose of a new imaging agent for patients with tumors that express HER3. This research aims to improve how we visualize and understand tumor response to treatment.

EGFR Mutation Positive Advanced Lung Cancer>2 yearsEfficacy phase (II)No Placebo Investigational Medicines Cost Reimbursement Partially RemoteNeurologyOncology

Crohn's Disease: Obefazimod Study

We are testing a new medication, obefazimod, for people with moderately to severely active Crohn's disease who haven't responded to other treatments. The study aims to see if it is more effective and safe compared to a placebo.

Crohn's Disease>2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementGastroenterologyInternal Medicine

Advanced Non-Small Cell Lung Cancer: Rilvegostomig Study

We are testing a new treatment called rilvegostomig in adults with advanced or metastatic non-small cell lung cancer. The study aims to evaluate its safety and effectiveness compared to existing therapies.

Advanced Lung CancerSafety phase (I)Efficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncology

Urothelial Cancer: Sacituzumab Govitecan Study

We are investigating a new treatment for patients with advanced urothelial cancer that cannot be removed by surgery. The study aims to see how effective and safe this treatment is compared to existing options.

Urothelial Cancer of the Renal Pelvis>2 yearsEfficacy phase (II)Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicineOncologyUrology

Ulcerative Colitis: GS-1427 Study

We are testing a new medication, GS-1427, for adults with moderately to severely active ulcerative colitis. The study aims to see if it can improve symptoms and achieve remission compared to a placebo.

Ulcerative Colitis1-2 yearsEfficacy phase (II)>20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteGastroenterologyInternal Medicine

Meningioma Treatment: Everolimus and 177Lu-DOTATATE

We are studying a new combination treatment for patients with grades 2 and 3 refractory meningioma. The goal is to see if this approach can help improve survival and manage tumor growth.

Malignant Meningiomas1-2 yearsEfficacy phase (II)11-15 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteNeurologyOncology

Whooping Cough Vaccine: Tdap-IPV Study

We are studying whether a booster shot of the Tdap-IPV vaccine helps prevent colonization by whooping cough bacteria in healthy adults after exposure. This research aims to improve vaccination strategies against whooping cough.

Whooping Cough≤3 monthsMonitoring phase (IV)No Placebo Standard Medicines Cost Reimbursement Partially RemoteInfectious Diseases

Scleroderma: Stem Cell Injections for Digital Ulcers

We are studying if injections of cultured fat cells can help heal stubborn digital ulcers in patients with scleroderma. This trial compares the treatment to a placebo to evaluate its effectiveness and safety.

Systemic Sclerosis>2 yearsEfficacy phase (II)6-10 visits Investigational Medicines Cost ReimbursementInternal MedicineRheumatology

Obstructive Sleep Apnea: Nacystelyn Inhaler Study

We are testing a new inhaler treatment for people with obstructive sleep apnea to see if it helps improve symptoms and reduce oxidative stress. The study also looks at the safety of this new treatment.

Obstructive Sleep Apnea≤3 monthsEfficacy phase (II)≤5 visits Standard Medicines Cost ReimbursementNeurologyPsychiatryPulmonology

Search Clinical Trials in the European Union